Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deciphering leukemic B-cell chronic lymphoproliferative disorders.

Valérie Ugo1, Nathalie Leporrier, Véronique Salaun

  • 1Laboratoire d'Hématologie, CHU Brest, France.

Leukemia & Lymphoma
|October 31, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Information borrowing in phase II randomized dose-ranging clinical trials in oncology.

BMC medical research methodology·2026
Same author

[Flow cytometry image atlas: lymphoproliferative syndromes - Additional images obtained on the XF1600].

Annales de biologie clinique·2026
Same author

How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clonal Lymphocyte Expansions and JAK-STAT Pathway Mutations Define a Pathogenic Continuum Driving Resistance to Gluten-Free Diet in Celiac Disease.

Gastroenterology·2026
Same author

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Cancer·2026
Same author

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Lancet (London, England)·2026
Same journal

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.

Leukemia & lymphoma·2026
Same journal

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
See all related articles

Diagnosing leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) is challenging. This study identified distinct subgroups within atypical B-CLPD, aiding in better classification and treatment strategies for these hematologic malignancies.

Area of Science:

  • Hematology
  • Oncology
  • Immunophenotyping

Background:

  • Leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) present diagnostic challenges.
  • Atypical cases require further subclassification for accurate prognosis and treatment.

Purpose of the Study:

  • To investigate atypical B-CLPD cases using a multicentric approach.
  • To identify homogeneous subgroups within B-CLPD for improved diagnostic and therapeutic strategies.

Main Methods:

  • Prospective study of 165 new consecutive leukemic B-CLPD patients with a Royal Marsden Hospital score ≤3.
  • Morphological examination, CD5, cyclin D1, CD20, and p27 expression analysis.

Main Results:

  • Morphology was diagnostic in only 20% of cases (all CD5 negative).

Related Experiment Videos

  • Cyclin D1 positivity (26 cases) indicated poorer survival, warranting systematic testing.
  • CD20 expression delineated two subgroups among CD5 positive, cyclin D1 negative B-CLPD: CD20 dim (17 patients) resembling B-cell chronic lymphocytic leukemia (B-CLL), and CD20 bright (51 patients) showing heterogeneity and lower p27, suggesting a proliferative component.

    • Conclusions:

    • Systematic cyclin D1 determination is recommended for atypical B-CLPD.
    • CD20 expression helps distinguish a homogeneous subgroup similar to B-CLL (CD20 dim).
    • The heterogeneous CD20 bright subgroup requires further genomic investigation due to potential proliferative and aggressive disease characteristics, suggesting exclusion from B-CLL therapeutic trials.